pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›COVID-19 Vaccine
drug · vaccine component
save

Coronavirus Disease 2019 (COVID-19) vaccine

Phase 3updated 3mo ago
by $SNY Sanofi🔗 ChEMBL
Phase 3
community read0 votes

🐶 often sniffed alongside

top 6
  • tagCardiology2 co-mentions · 1 sources
  • drugUndisclosed1 co-mentions · 1 sources
  • companyBarts Charity1 co-mentions · 1 sources
  • tagVaccine1 co-mentions · 1 sources
  • drugCoronavirus Disease 2019 (COVID-19) vaccine 11 co-mentions · 1 sources
  • drugundisclosed Covid-19 vaccine1 co-mentions · 1 sources

Vaccine component drug with a maximum clinical stage of Approval, with an approval for covid-19.

targets

Spike glycoprotein

all catalysts(0)

nothing on the calendar yet

Trials studying Coronavirus Disease 2019 (COVID-19) vaccine

  • phase1Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19active not recruitingn=20
  • —COVID-19 Vaccines International Pregnancy Exposure Registrycompletedn=1,184
  • EP1Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mixactive not recruitingn=20
  • —A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenzaactive not recruitingn=999
  • phase1A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adultsrecruitingn=225
  • phase4Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19active not recruitingn=285,000
  • phase2Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.completedn=887
  • phase2SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Canceractive not recruitingn=63
more trials →

News(10)

  • BioNTech vets get $25M seed funding for virtual cancer surveillance startup
    BioNTech’s former chief strategy officer Ryan Richardson had a front seat to the creation of a Covid vaccine, and then helped orchestrate BioNTech’s return to its pursuit of new cancer therapies. I…
    endpoints · 7h ago
  • FDA approves Moderna’s mRNA flu vaccine
    The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory turnaround.
    biopharma_dive · 4d ago
  • BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine
    Lower vaccine demand across every market and more acute pressures in Germany led BioNTech to lower the midpoint of its sales outlook by almost 20%.
    biospace · 6d ago
  • BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
    BioNTech’s leadership transition was announced earlier this year, with CEO Ugur Sahin and CMO Özlem Türeci leaving to start a new mRNA company. Guido Oelkers of Swedish Orphan Biovitrum AB will tak…
    biospace · 7d ago
  • STAT+: BioNTech names Guido Oelkers its new CEO
    Guido Oelkers will take over as the new CEO of BioNTech, replacing company cofounder Ugur Sahin.
    stat · 7d ago
  • After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
    One of the most closely watched vacancies in biopharma has now been filled, with Sobi CEO Guido Oelkers, Ph.D., moving across to take up the top job at mRNA pioneer BioNTech.
    fiercebiotech · 7d ago
  • STAT+: Trump promised redemption for troops who refused Covid shots. A year later, many are still waiting
    Veterans who want to rejoin the military are often bogged down in bureaucratic red tape.
    stat · 18d ago
  • Agenus surges on study pivot; Apnimed lines up an IPO
    Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.
    biopharma_dive · 28d ago
  • Nominee for key federal health role has a history of questioning vaccines
    Sean Kaufman's views on vaccines may put him at odds with Sen. Bill Cassidy during next week's confirmation hearing.
    stat · 1mo ago
  • HHS advances plan to pay out Covid-19 vaccine injury claims
    A newly proposed HHS rule would establish a compensation mechanism for people who claim they were injured by Covid-19 vaccines, as a key panel that oversees broader vaccine injury payments remains…
    endpoints · 1mo ago
view all news mentions →
brand
COVID-19 Vaccine
trade names
Vaxzevria (previously covid-19 vaccine astrazeneca)
MOA
Spike glycoprotein vaccine antigen
indication
Coronavirus Disease 2019 (COVID-19)
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 10m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?